The Psychedelic Therapy Podcast1 Touko 2020

Dr. David Rabin MD, PhD | Creating Safety for Psychedelic Healing

My guest today is Dr. David Rabin, a psychiatrist, PhD neuroscientist, inventor, and avid proponent of psychedelic medicine.

On the show we discuss the neuroscience behind the inner healer and how in the correct setting, psychedelics can help to repattern trauma. We talk about how the attachment to an identity of depression can actually create depressive symptoms. Dr. Rabin shares his work with Modern Spirit who is helping to organize the largest epigenetic study of psychedelics, and we go deep on the default mode network.

In addition to his psychiatric practice, Dr. Rabin is the chief innovation officer, co-founder and co-inventor at Apollo Neuroscience, a scientifically-validated wearable system to improve focus, sleep and access to meditative states. He is helping to organize one of the largest epigenetic studies of psychedelic medicines in collaboration with colleagues at Yale, USC, Mt. Sinai, Modern Spirit, and MAPS. He is also the co-founder and executive director of the Board of Medicine, a nonprofit focused on improving the safety and effectiveness of medication-based treatments for patients and healthcare providers.

If you want support your client’s inner healer, the most important thing is to make them feel safe. Listen in, as Dr. Rabin shows us how.

Links

Timestamps

:06 When Dr. Rabin first became aware of the healing power of psychedelics
:12 How psychedelics work to repatterning trauma
:16 Creating a set and setting of safety which allows the inner healer to work
:24 Techniques does Dr. Rabin use to create safety for his patients
:36 How attachment to an identity of depression creates depressive symptoms
:43 Default mode network
:47 Dr. Rabin and Modern Spirit’s epigenetic psychedelic study
:55 Dr. Rabin addresses psychedelic therapists

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(64)

Ismail Lourido Ali (MAPS): The Work No Executive Order Can Do

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali...

21 Huhti 1h 10min

Robin Arnott & Sandeep Prakash: Training for Psychedelic Surrender

Can we practice the art of surrender before the first dose?Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that...

25 Huhti 202555min

Joshua White: Who You Gonna Call? Fireside

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer sup...

13 Helmi 20251h 14min

Tom Feegel: Ibogaine for Cognitive Enhancement

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remark...

27 Tammi 20251h 6min

Juan Pablo Capello: A Wakeup Call for Ketamine Telehealth Companies

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of car...

20 Marras 20241h 4min

Natalie Lyla Ginsberg (MAPS): The FDA, MDMA, and the Future of Psychedelic Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of...

28 Loka 20241h 3min

Tricia Eastman & Joseph Barsuglia: Ibogaine is Miracle Grow for the Brain

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, orig...

18 Loka 20241h 9min

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the differe...

8 Elo 202446min